Nanobiotix reports 1H24 results and provides update
- Co reports 1H24 (Jun) revenue and other income increased to €9.3 mln from €3.3 mln last year, primarily resulting from services and product supply revenue linked to the exclusive licensing, co-development, and commercialization agreement with Janssen.
- Co expects several clinical milestones over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer.
- "We continue to make strong progress advancing our nanoparticle-based therapeutic approach with lead candidate NBTXR3, which is part of our global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. The agreement is designed to realize significant therapeutic and market opportunities in solid tumor cancers worldwide, starting with lung and head and neck. We also continue to establish additional expansion opportunities across multiple cancer settings as part of our ongoing collaboration with MD Anderson." said Laurent Levy, co-founder of Nanobiotix and chairman.